Clinically grounded, game-based and always available — MIRDC’s AI system is redefining how children learn to communicate.
Updated
January 8, 2026 6:32 PM
A child practicing with a speech therapist. PHOTO: FREEPIK
Speech and language delays are common, yet access to therapy remains limited. In Taiwan, only about 2,200 licensed speech-language pathologists serve hundreds of thousands of children who need support—especially those with autism spectrum disorders or significant communication challenges. As a result, many children miss crucial periods of language development simply because help isn’t available soon enough.
MIRDC’s new AI-powered interactive speech therapy system aims to close that gap. Instead of focusing solely on articulation, it targets a wider range of language skills that many children struggle with: oral expression, comprehension, sentence building and conversational ability. This makes it a more complete tool for childhood speech and language development.
The system combines game-based learning, AI-driven guidance and automated language assessment into one platform that can be used both in clinics and at home. This integrated design helps children practice more consistently, providing therapists and parents with clearer insight into their progress.
The interactive game modules are built around clinically validated therapy methods. Imitation exercises, picture cards, storybooks and conversational prompts are turned into structured game levels, each aligned with a specific developmental goal. This step-by-step approach helps children move from simple naming tasks to more complex comprehension and response skills, all within a sequenced curriculum.
A key differentiator is the system’s real-time AI speech interpretation. As the child talks, the AI analyzes the response and generates tailored therapeutic cues—such as imitation, modeling, expansion or extension—based on the conversation. These are the same strategies used by speech-language pathologists, but now children can access them continuously, supporting more effective at-home practice and reducing long gaps between sessions.
After each session, the system automatically conducts a data-driven language assessment using 20 objective indicators across semantics, syntax and pragmatics. This provides clinicians and families with measurable, easy-to-understand reports that show how the child is progressing and which skills need more attention—something many traditional tools do not offer.
By offering a personalized, scalable and clinically grounded solution, MIRDC’s AI therapy system helps address the ongoing shortage of speech-language services. It doesn’t replace therapists; instead, it extends their reach, allows for more consistent practice and helps families support their child’s communication at home.
As an added recognition of its impact, the system recently earned two R&D 100 Awards, including the Silver Award for Corporate Social Responsibility. But at its core, the project remains focused on a simple mission: making high-quality speech therapy accessible to every child who needs a voice.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.